noscript

News and Announcements

SUDA Granted Canadian Patent for SUD-002

  • Published April 12, 2016 3:34PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

12th April 2016, ASX Announcement

SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug deliver, is pleased to announce that the Canadian Intellectual Property Office has issued Canada Patent number 2,673,049, covering the Company’s novel oral spray of ondansetron (SUD-002). The patent is entitled “Stable Anti-nausea Oral Spray Formulations and Methods” and has an expiry date of  21 December 2017.

This is the second patent to be issued in Canada for SUDA’s SUD-002 oral spray to treat nausea and vomiting induced by chemotherapy, radiotherapy and also in post-operative settings. It is part of the broad intellectual property portfolio acquired by SUDA from NovaDel in 2013. The patent has been granted or is pending in other major jurisdictions.

To view the full article please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now